Alzheimer's disease drug development pipeline: 2023
University of Nevada, Las Vegas · Cleveland Clinic Lerner College of Medicine · +2 more institutions
Abstract
Drugs that prevent the onset, slow progression, or improve cognitive and behavioral symptoms of Alzheimer's disease (AD) are needed.
We searched ClinicalTrials.gov for all current Phase 1, 2 and 3 clinical trials for AD and mild cognitive impairment (MCI) attributed to AD. We created an automated computational database platform to search, archive, organize, and analyze the derived data. The Common Alzheimer's Disease Research Ontology (CADRO) was used to identify treatment targets and drug mechanisms.
Citation impact
- FWCI
- 62.07
- Percentile
- 100%
- References
- 23
Authors
6- JLJeffrey L. CummingsCorresponding
University of Nevada, Las Vegas
- YZYadi Zhou
Cleveland Clinic Lerner College of Medicine
- GLGaram Lee
University of Nevada, Las Vegas
- KZKate Zhong
University of Nevada, Las Vegas
- JRJorge Ramón Fonseca Cacho
Cleveland Clinic Lerner College of Medicine, Case Western Reserve University
Topics & keywords
- Drug development
- Disease
- Pipeline (software)
- Drug
- Medicine
- Intensive care medicine
- Neuroscience
- Psychology
- Good health and well-being
Funding
- ADAlzheimer's Drug Discovery FoundationAward: P20GM109025
- NINational Institute on AgingAwards: P20GM109025, U01AG073323, 3R01AG066707-01S1, R56AG074001, R01AG076448, R01AG066707, R35AG71476, P20AG068053, R01AG053798
- NINational Institute of General Medical SciencesAwards: P20AG068053, P20GM109025
- NINational Institute of Neurological Disorders and StrokeAward: U01NS093334